HomeGUTS • NASDAQ
add
Fractyl Health Inc
Previous close
$0.46
Day range
$0.45 - $0.47
Year range
$0.38 - $3.03
Market cap
73.37M USD
Avg Volume
2.75M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 23.28M | -7.65% |
Net income | -43.73M | -75.12% |
Net profit margin | — | — |
Earnings per share | -0.07 | 86.54% |
EBITDA | -23.00M | 7.93% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 81.54M | 20.86% |
Total assets | 121.40M | 12.33% |
Total liabilities | 111.94M | 40.54% |
Total equity | 9.46M | — |
Shares outstanding | 158.65M | — |
Price to book | 7.63 | — |
Return on assets | -49.40% | — |
Return on capital | -89.48% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -43.73M | -75.12% |
Cash from operations | -21.34M | -25.26% |
Cash from investing | -3.00K | 98.71% |
Cash from financing | 25.22M | 37,544.78% |
Net change in cash | 3.88M | 122.58% |
Free cash flow | -16.80M | -65.41% |
About
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
Founded
2010
Headquarters
Website
Employees
101
